Cytokinetics (CYTK) announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion recommending marketing authorization in the European Union for MYQORZO, a cardiac myosin inhibitor, for the treatment of symptomatic obstructive hypertrophic cardiomyopathy in adult patients. A final decision is anticipated from the European Commission in the first quarter of 2026.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CYTK:
- Promising Outlook for Cytokinetics: Buy Rating Supported by Aficamten’s Advantages in HCM Treatment
- CRNX, CYTK, MDGL, SLNO: Top Analyst Outlines Her ‘Top Biotech Ideas for 2026’
- Promising Prospects for Cytokinetics’ Aficamten in oHCM and nHCM Markets
- Cytokinetics supports AHA initiative to improve care for people living with HCM
- Cytokinetics Appoints New Executive VP and CLO